Literature DB >> 21558312

The antagonists but not partial agonists of glucocorticoid receptor ligands show substantial side effect dissociation.

Xiao Hu1, Sarah Du, Cansu Tunca, Timothy Braden, Kelly R Long, Jamie Lee, Elizabeth G Webb, Jessica D Dietz, Susan Hummert, Sharon Rouw, Shridhar G Hegde, R Keith Webber, Mark G Obukowicz.   

Abstract

A synthetic glucocorticoid receptor (GR) ligand with the efficacy of a glucocorticoid, but without the accompanying side effects, would meet an unmet medical need for the treatment of inflammatory diseases. It was hypothesized that a GR ligand that shifted helix 12 in a manner distinct from an agonist and an antagonist would confer a distinct GR conformation, resulting in differential gene expression and, ultimately, dissociation of antiinflammatory activity from side effects. A structural feature expected to interfere with helix 12 was incorporated into a nonsteroidal, tricyclic scaffold to create novel, high-affinity, and selective GR ligands that manifested a dual function in cellular assays, partial but robust agonist activity for inflammatory cytokine inhibition, and full antagonist activity for reporter gene activation. In contrast, analogs not likely to hinder helix 12 exhibited partial agonist activity for reporter gene activation. The requirement of full antagonist activity for substantial side effect dissociation was demonstrated in primary human preadipocytes, hepatocytes, and osteoblasts in which effects on adipogenesis, key genes involved in gluconeogenesis, and genes important for bone formation were examined, respectively. The dissociated GR ligands, despite lacking significant reporter gene activation, weakly recruit a limited number of coactivators such as peroxisomal proliferator-activated receptor-γ coactivator 1α. Transcriptional activation was sensitive to both peroxisomal proliferator-activated receptor-γ coactivator 1α and GR levels, providing a basis for cell-selective modulation of gene expression. The antiinflammatory activity of the dissociated ligands was further demonstrated in mouse models of inflammation. Together these results suggest that these ligands are promising candidates with robust antiinflammatory activity and likely dissociation against glucocorticoid-induced side effects.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21558312     DOI: 10.1210/en.2010-1447

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  18 in total

Review 1.  The multiple facets of glucocorticoid action in rheumatoid arthritis.

Authors:  Ulrike Baschant; Nancy E Lane; Jan Tuckermann
Journal:  Nat Rev Rheumatol       Date:  2012-10-09       Impact factor: 20.543

2.  Predicting the probability of successful efficacy of a dissociated agonist of the glucocorticoid receptor from dose-response analysis.

Authors:  Daniela J Conrado; Sriram Krishnaswami; Satoshi Shoji; Sheela Kolluri; Judith Hey-Hadavi; Dorothy McCabe; Ricardo Rojo; Brinda K Tammara
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-05-13       Impact factor: 2.745

3.  Protein phosphatase 1 alpha enhances glucocorticoid receptor activity by a mechanism involving phosphorylation of serine-211.

Authors:  Melanie Patt; Joël Gysi; Nourdine Faresse; John A Cidlowski; Alex Odermatt
Journal:  Mol Cell Endocrinol       Date:  2020-06-22       Impact factor: 4.102

Review 4.  Structural insights into glucocorticoid receptor function.

Authors:  Filipp Frank; Xu Liu; Eric A Ortlund
Journal:  Biochem Soc Trans       Date:  2021-11-01       Impact factor: 4.919

5.  Deacylcortivazol-like pyrazole regioisomers reveal a more accommodating expanded binding pocket for the glucocorticoid receptor.

Authors:  Jessica A O Zimmerman; Mimi Fang; Bintou Doumbia; Alexis Neyman; Ji Hyeon Cha; Michael Thomas; Bonnie Hall; Meng Wu; Anne M Wilson; Miles A Pufall
Journal:  RSC Med Chem       Date:  2020-12-08

6.  Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies.

Authors:  Ekaterina Lesovaya; Alexander Yemelyanov; Kirill Kirsanov; Alexander Popa; Gennady Belitsky; Marianna Yakubovskaya; Leo I Gordon; Steven T Rosen; Irina Budunova
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

7.  Disruption of a key ligand-H-bond network drives dissociative properties in vamorolone for Duchenne muscular dystrophy treatment.

Authors:  Xu Liu; Yashuo Wang; Jennifer S Gutierrez; Jesse M Damsker; Kanneboyina Nagaraju; Eric P Hoffman; Eric A Ortlund
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-11       Impact factor: 11.205

8.  Chemical systems biology reveals mechanisms of glucocorticoid receptor signaling.

Authors:  Nelson E Bruno; Jerome C Nwachukwu; Sathish Srinivasan; Charles C Nettles; Tina Izard; Zhuang Jin; Jason Nowak; Michael D Cameron; Siddaraju V Boregowda; Donald G Phinney; Olivier Elemento; Xu Liu; Eric A Ortlund; René Houtman; Diana A Stavreva; Gordon L Hager; Theodore M Kamenecka; Douglas J Kojetin; Kendall W Nettles
Journal:  Nat Chem Biol       Date:  2021-01-28       Impact factor: 15.040

Review 9.  Discovery of Compound A--a selective activator of the glucocorticoid receptor with anti-inflammatory and anti-cancer activity.

Authors:  Ekaterina Lesovaya; Alexander Yemelyanov; Amanda C Swart; Pieter Swart; Guy Haegeman; Irina Budunova
Journal:  Oncotarget       Date:  2015-10-13

10.  Selective Activator of the Glucocorticoid Receptor Compound A Dissociates Therapeutic and Atrophogenic Effects of Glucocorticoid Receptor Signaling in Skin.

Authors:  Anna Klopot; Gleb Baida; Pankaj Bhalla; Guy Haegeman; Irina Budunova
Journal:  J Cancer Prev       Date:  2015-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.